PTC/SB/08s (06-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resp nd to a collection of information unless it contains a valid OMB control number. Application Number

Filing Date

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)					First Named Inventor Domey								
					Art Unit								
(NOL TOT :	Subili	ission under 37 CFR	Exam	Examiner Name									
			Attorn	Attorney Docket Number			1307RPL-2				\neg		
				_				_					_
					U.S.	PATENTS					Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date		of cited Desument				Pages,Columns Relevant Passa Figures Appear			
	1												
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click	the A	vdd	button.		Add		
			U.S.P	ATENT	ATENT APPLICATION PUBLICATIONS						Remove		\neg
Examiner Initial*	Cite No	Publication Number	Kind Code ¹				name of Patentee of Applicant Rela			Releva	es,Columns,Lines where evant Passages or Relevant rres Appear		
	1												
If you wis	h to a	i dd additional U.S. Publ	shed Ap	plication	citatio	ı n informati	on ple	eas	se click the Ad	d button	Add		-
				FOREIG	SN PAT	ENT DOC	UME	N	rs		Remove		
Examiner Initial*	miner Cite Foreign Document Number³ Code2				Publication Date	on [Αp	me of Patente plicant of cited cument	or v	vhere Rel	or Relevant	+.	
	1	2004/014611	wo			2004-02-1	19	Do	orney et al.				
	2	2003/035992	wo			2003-05-0)1	Pil	ja				
	3	2003/095847	wo			2003-11-2	20	Sm	nith				П

		_	
	Application Number		
INFORMATION DIGGS COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Dome	ey
(Not for submission under 37 CFR 1.99)	Art Unit		
(Examiner Name		
	Attorney Docket Number	er	1307RPL-2

	4	35441/93	AU		1993-09-30	The Visador Co		
If you wish	h to a	dd additional Foreign F	atent Document	citation	information pl	ease click the Add buttor	Add	
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	aminer Cite No obliner, city and country where published. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, settled, symposium, catalog, etc), date, pages(s), volume-issue number(s), pages(s), pages(s)						Τs	
	1	International Search Re	eport dated May 20	, 2005, 1	for PCT Applicat	tion No. PCT/AU2005/0002	82	
If you wish	h to a	dd additional non-pater	nt literature docu	ment cit	tation informati	on please click the Add I	outton Add	
			EX	AMINE	R SIGNATUR	E		
Examiner	Signa	ture				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. S Applicant is to place a check mark here if

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

English language translation is attached.

Application Number Filing Date Filing Date Filing Date First Number Indignate First Number Indignate First Number Indignate Art Unit Examiner Name Attorney Docket Number I 3807894-2

CERTIFICATION STATEMENT

Diagra can	37 CF	P 1 97	and 1	QR to	make the	annronriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Mark L. Yaskanın/	Date (YYYY-MM-DD)	2006-09-05
Name/Print	Mark L. Yaskanin	Registration Number	45246

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.